Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone and two pounds (7.3kg) each over 10 months. Unhealthy blood sugar ...

Patients with obesity often report being shamed and stigmatized in medical settings. How can physicians address weight ...

Costing an estimated £11.3bn in total, the Abidjan-Lagos Corridor Highway Development Project will enable faster and more ...

Portugal has emerged as a compelling destination for American investors, especially in real estate and lifestyle sectors. The ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly stocks displayed a major rise after the announcement of a new oral weight-loss drug that has put pressure on its ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Find insight on Novo Nordisk, ResMed and more in the latest Market Talks covering the Health Care sector.

Luma Vision describes Verafeye as a catheter-based imaging system that provides real-time, two and four-dimensional, ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...